The CDNF protein treatment for Parkinson’s disease

2018 | Herantis Pharma and the team of the Institute of Biotechnology in University of Helsinki

The CDNF protein treatment for Parkinson’s disease developed by Herantis Pharma and the team of the Institute of Biotechnology in University of Helsinki has been shown to be an effective protector of neurons, both alleviating symptoms and also potentially halting the progress of the disease. The development of the biological medical preform is now in the phase of placebo controlled clinical trials in European Parkinson’s disease research centres.